UroGen Pharma Ltd (URGN) is an innovative biotechnology company focused on the development of advanced therapies for urological diseases, including urothelial carcinoma and bladder cancer. Leveraging its proprietary reverse thermal gel technology, the company enables targeted, sustained drug delivery, maximizing treatment efficacy while reducing systemic side effects. UroGen's strong clinical pipeline underscores its commitment to addressing substantial unmet medical needs in the oncology space, positioning the company as a potential leader in the urological oncology market and significantly improving patient outcomes.
| Revenue (TTM) | $140.49M |
| Gross Profit (TTM) | $126.24M |
| EBITDA | $-107.90M |
| Operating Margin | -39.80% |
| Return on Equity | -1481.00% |
| Return on Assets | -27.00% |
| Revenue/Share (TTM) | $2.88 |
| Book Value | $-2.55 |
| Price-to-Book | 19.27 |
| Price-to-Sales (TTM) | 14.38 |
| EV/Revenue | 14.59 |
| EV/EBITDA | -2.63 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 151.60% |
| Shares Outstanding | $48.72M |
| Float | $43.20M |
| % Insiders | 3.62% |
| % Institutions | 101.42% |
Volatility is currently expanding
Conference Call and Webcast Scheduled for Wednesday, August 5th, 2026, at 10:00 AM ET Conference Call and Webcast Scheduled for Wednesday, August 5th, 2026, at 10:00 AM ET
UroGen Pharma is shifting NMIBC treatment from surgery to office-based chemoablative therapy with ZUSDURI, driving a differentiated investment thesis. ZUSDURI revenue surged 109% sequentially to $29.2M in Q1 2026; repeat prescribers and workflow integration signal durable adoption and positive operating leverage. URGN's premium valuation is justified by a $5B+ TAM, durable clinical data, patent protection to 2044, and a de-risked pipeline including UGN-103.
PRINCETON, N.J., July 15, 2026 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd.
According to this Form 4 filing, the CMO of UroGen Pharma sold 10,000 shares at $40.00 per share, totaling $400,000 in transaction proceeds. The sale represented 8% of the insider's direct equity holdings in the company, as reported in the Form 4.
FDA clearance enables initiation of a planned Phase 1 clinical study evaluating local intravesical administration of UGN-501, with patient enrollment expected to begin in Q4 2026 UGN-501 is a differentiated investigational next-generation oncolytic virus designed to combine direct tumor cell destruction with anti-tumor immune activation PRINCETON, N.J., July 08, 2026 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd.
Does Urogen Pharma (URGN) have what it takes to be a top stock pick for momentum investors? Let's find out.
10,000 shares were sold for a transaction value of ~$350,000 at a weighted average price of around $35.01 per share on June 22, 2026. The sale represented 7.15% of Mark Schoenberg's direct holdings, reducing his position from 139,763 to 129,763 shares of common stock.
PRINCETON, N.J., June 05, 2026 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd.
Agreement reinforces the value of UroGen's innovation and reflects the strength of the Company's intellectual property portfolio Teva will be granted a non-exclusive license to sell its generic version of JELMYTO beginning on September 15, 2030, if approved by the FDA PRINCETON, N.J., June 02, 2026 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd.
PRINCETON, N.J., June 01, 2026 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotechnology company focused on transforming the treatment of urothelial and specialty cancers, today announced that management will present at the Goldman Sachs 47th Annual Global Healthcare Conference to take place on June 8-10, 2026.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on URGN and any ticker you trade — then tracks every position and per-strategy win rate.
